Skip to content
Bending the Curve Trial by Trial
?

Mortality and second cancer incidence after treatment for testicular cancer: psychosocial health and lifestyle are modifiable prognostic factors

Phase observationalN = 775

Population
Long-term survivors of testicular cancer diagnosed 1980 to 1994 who had taken part in a quality-of-life survey
Design
Cohort of long-term survivors diagnosed 1980 to 1994 who had previously taken part in a quality-of-life survey. Twenty-year mortality and non-germ-cell second cancer incidence were compared between a surgery group (272) and a platinum-based chemotherapy group (503), with Kaplan-Meier and Cox analyses including patient-reported adverse health outcomes.
Arms
  • All participants (experimental, n = 775): Surgery (272) or platinum-based chemotherapy (503)
People
Fosså SD
Show the numbers
Results reported for Mortality and second cancer incidence after treatment for testicular cancer: psychosocial health and lifestyle are modifiable prognostic factors
EndpointAnalysisAll participantsControlEffect
Cumulative overall mortalityAll 775 participantsfinalFosså 202214% at 20 y (11.8–16.8%)—Cumulative overall 20-year mortality for all participants. The abstract also reports that, compared with a low-risk group (no patient-reported adverse health outcomes; 446 men), mortality was further increased by 80% (with the exception of neurotoxicity) in a medium-risk group (one or two outcomes; 278 men), and that in a high-risk group (three outcomes; 47 men) overall mortality and cancer mortality were eight-fold and five-fold increased.
Results reported for Mortality and second cancer incidence after treatment for testicular cancer: psychosocial health and lifestyle are modifiable prognostic factors
EndpointAnalysisAll participantsControlEffect
Cumulative overall mortalityAll 775 participantsfinalFosså 202214% at 20 y (11.8–16.8%)—Cumulative overall 20-year mortality for all participants. The abstract also reports that, compared with a low-risk group (no patient-reported adverse health outcomes; 446 men), mortality was further increased by 80% (with the exception of neurotoxicity) in a medium-risk group (one or two outcomes; 278 men), and that in a high-risk group (three outcomes; 47 men) overall mortality and cancer mortality were eight-fold and five-fold increased.
Primary publication: Fosså SD, Dahl AA, Thorsen L, Hellesnes R, Kiserud CE, Tandstad T, et al. Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors. J Clin Oncol. 2022;40(23):2588-2599. PubMedDOI

Appears in

Sources

  1. Fosså SD, Dahl AA, Thorsen L, Hellesnes R, Kiserud CE, Tandstad T, et al. Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors. J Clin Oncol. 2022;40(23):2588-2599.

    PubMedDOI